BUSINESS
Manipal Hospitals buys out Bengaluru-based Vikram Hospital from Multiples Private Equity Fund
Set up in 2009, Vikram Hospital is a 200-bedded high end tertiary care facility located in the heart of Bengaluru on Millers Road, known for its clinical expertise in the fields of Cardiac and Neuro Sciences.
BUSINESS
MSD's women health spin-off Organon takes off in India
Organon has a portfolio of contraceptive and fertility brands anchored by market exclusivity for ImplanonNxt (etonogestrel implant) that has long-term growth potential.
BUSINESS
Biological E's COVID Vaccine: Govt to pay Rs 1500 crore advance to procure 30 crore doses
The COVID-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2 clinical trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months.
INDIA
SC questions govt’s vaccination policy, seeks data on purchase history, ordered quantities, supplies
The Court also asked the Centre to provide an outline for how and when the Central government seeks to vaccinate the remaining population in phases 1, 2 and 3 and the steps being taken by the Central Government to ensure drug availability for mucormycosis.
BUSINESS
COVID-19 vaccination becomes more convenient as pvt hospitals, labs, pharmacy chains reach out to customers
Apollo Hospitals has completed 1 million vaccinations across 80 locations in India so far. It plans to make it into a million every week in June and double that in July. Karnataka permits even diagnostic chains. Only problem is that there is no cap on the vaccine administration fee.
BUSINESS
COVID-19 treatment | Haffkine Biopharma to produce 22.8 crore doses per annum of Covaxin
“We have been given a timeline of eight months and the work is being executed on a war footing," said Dr. Sandeep Rathod, Managing Director of Haffkine BioPharma.
BUSINESS
DCGI exempts post approval bridging trials, CDL testing for imported vaccines approved by select regulators
The exemption will however limited to COVID-19 vaccines approved in India for restricted use in emergency situation which are already approved for restricted use by USFDA, EMA, UK MHRA, PMDA Japan or listed in WHO Emergency Use Listing (EUL) and which are well established vaccine from the stand point that millions of individuals have already been vaccinated with the said vaccines.
BUSINESS
Govt to pick 55 applicants for the new pharma PLI scheme offering Rs 15,000 crore sops
"An applicant, through a single application, can apply for more than one product and the products applied by an applicant can be in any of the three categories," DoP said in a statement.
BUSINESS
Metropolis Healthcare MD sees strong FY22 as COVID tests surge, other tests undented
Metropolis Healthcare is planning to expand its network and remains optimistic about sustaining the strong performance it reported in FY21. Non-COVID testing remains strong unlike the disruption caused by the complete lockdown last year.
BUSINESS
Biological E enters licensing pact with Canada firm Providence Therapeutics for mRNA vaccine
As part of the agreement, BE will conduct pivotal trial and seek emergency use authorisation in India and other jurisdictions. Providence will provide the necessary technology transfer for BE to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses.
BUSINESS
Eli Lilly gets DCGI emergency use approval for COVID-19 antibody cocktail drug
Lilly said it is engaged in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with COVID-19.
BUSINESS
Aurobindo Pharma, Vaxxinity seek DCGI nod to begin Phase-2/3 of COVID-19 jab UB-612
N Govindarajan, Managing Director of Aurobindo Pharma, at the company's earnings call on Monday said that the drug maker expects the approval of UB-612 in December or January next year if everything goes according to their plan.
BUSINESS
Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its R&D business
Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation R&D business, bigger than most of its peers, developing a potential pipeline of drug assets
BUSINESS
Not authorised any third party to distribute COVID-19 vaccine in India, say RDIF and Dr Reddy's
"In last few days, there have been several unsubstantiated reports and claims from various quarters in India on alleged tie-ups for the Sputnik V Vaccine," a statement from RDIF and Dr Reddy;s said.
BUSINESS
It takes about 4 months to produce and release one Covaxin batch into market, says Bharat Biotech
Bharat Biotech statement comes at a time when the company said it has the capacity to produce 10-12 million doses of vaccine, but there were reports in media that the actual supplies was far less than what was being announced.
BUSINESS
Sun Pharma joins biosimilars race, to target assets with patent expiries in 7-10 years
Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on R&D.
BUSINESS
COVID-19 vaccine | UNICEF signs supply agreement with Russian Direct Investment Fund for Sputnik V
Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing from WHO, to confirm the quality, safety and efficacy of the vaccine.
BUSINESS
Bharat Biotech enters MoU with GCVC to produce Covaxin drug substance
If everything goes as per the schedule, the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech do do fill and finish of the vaccine. Hester will be investing about Rs 40 crores on this project.
BUSINESS
Zydus Cadila to seek emergency use approval for its COVID-19 vaccine in next 2 weeks
"We have capacity to produce 1 crore doses (10 million) per month. With partnerships with other manufacturers and debottlenecking and improving on yields at our own plant, we will be able to expand capacity to 2.5-3 crore (25-30 million doses) next 4-6 months," Sharvil Patel, Managing Director, Cadila Healthcare said.
BUSINESS
Strides Pharma says biotech associate Stelis in talks with global vaccine cos for manufacturing deal
The company declined to name the vaccine developer, but said it is accelerating the vaccine block infrastructure with ability to cater to multiple vaccine types including viral vector, protein subunit, RNA and DNA.
BUSINESS
Government says working with Pfizer for 'earliest possible import' of COVID vaccine
Buying vaccines internationally is not similar to buying off-the- shelf items. Vaccines are in a limited supply and companies have their own priorities, game plans and compulsions, the government has said.
BUSINESS
Lupin gets $50 million from Boehringer Ingelheim as 'milestone payment' for anti-cancer drug
Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company's novel oncology compound for difficult-to-treat cancers.
BUSINESS
Bharat Biotech submits fresh request before Brazilian regulator for Covaxin GMP certificate
Brazilian regulator Anvisa had in March denied a certificate for good manufacturing practices to Bharat Biotech citing certain violations of GMP at Bharat Biotech facility. Anvisa’s clearance is a necessary step for the country’s process of authorising this vaccine for emergency use.
BUSINESS
Zydus Cadila seeks permission from DCGI to test its COVID-19 antibody cocktail on humans
Zydus said the monoclonal antibody cocktail ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies and has demonstrated the ability to neutralise SARS-CoV-2 both in vitro and in animal studies.
